Vanda Pharmaceuticals Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mihael H. Polymeropoulos
- Full Time Employees
- 368
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2200 Pennsylvania Avenue NW Washington DC United States of America 20037
- IPO Date
- Apr 12, 2006
- CIK
- 0001347178
- Website
- vandapharma.com
- Similar Companies
- Business
- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) develops and commercializes innovative biopharmaceutical therapies focused on addressing high unmet medical needs in central nervous system disorders, sleep-wake conditions, psychiatric illnesses, and inflammatory diseases worldwide; the company, founded in 2003 and headquartered in Washington, DC, markets HETLIOZ (tasimelteon) for non-24-hour sleep-wake disorder and Smith-Magenis syndrome-associated nighttime sleep disturbances, including the LQ oral suspension formulation; Fanapt (iloperidone) for schizophrenia and acute bipolar I disorder, with a long-acting injectable formulation in development; and PONVORY (ponesimod) for multiple sclerosis, pursuing indications in psoriasis and ulcerative colitis with investigational new drug applications accepted by the FDA. Its pipeline encompasses tradipitant (VLY-686), a neurokinin-1 receptor antagonist for gastroparesis, motion sickness, and atopic dermatitis; Bysanti (milsaperidone) for bipolar I disorder, schizophrenia, and major depressive disorder; imsidolimab, licensed from AnaptysBio in February 2025 for generalized pustular psoriasis and potential expansion into other IL-36-related inflammatory conditions; VSJ-110 for dry eye; VPO-227 for secretory diarrhea disorders including cholera; VTR-297 for hematologic malignancies and onychomycosis; VQW-765 for social/performance anxiety; and VGT-1849B, which received FDA orphan drug designation for polycythemia vera, among others. Vanda operates globally with a subsidiary in the United Kingdom and targets rare diseases, neurology, psychiatry, and immunology patient populations through specialized sales forces and marketing campaigns. Recent developments include the $100 million acquisition of PONVORY from Johnson & Johnson, enabling commercial launch in the multiple sclerosis market and new indication pursuits; FDA approval and commercial rollout of Fanapt for acute bipolar I disorder; a global licensing agreement with AnaptysBio for imsidolimab development and commercialization; positive clinical results for tradipitant in preventing GLP-1 induced nausea and vomiting; a collaborative framework with the FDA to resolve disputes; and unsolicited acquisition proposals from Future Pak and Cycle Pharmaceuticals in 2024, which the company reviewed but did not pursue, reflecting ongoing strategic interest amid robust revenue growth to $267.7 million in 2024.
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200-Day Moving Average – Time to Sell?
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Increase in Short Interest
Contrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX)
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving Average – Should You Sell?
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods